Monday, December 23, 2019 9:49:30 AM
My only concern is that he is again ahead of his timelines.
I have no doubt that strontium 89 is going to be succes .
But the growth rate remains to be seen.
And also the other uses for strontium could be a succes.
Denis is a very good communicator.
Also talked about the glaucome . i'm sure this is something that could raise attention from big pharma . i think this partnership alone is worth over 200 million .
The liver cancer drug is a far stretch for the moment ,that is going to take time .so not expecting much of it soon.
He said nothing about the autistic drug ,nothing at all.
He should adres the status of that drug .
Video was good for more attention.
Don't think the buying of recent week is retail.
Someone is accumulating at a slow pace ,but because of the low float its not easy to keep the price in check.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM